ESC 365 - Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-

ESC Premium Access

Thrombin activatable fibrinolysis inhibitor promotes development of chronic thromboembolic pulmonary hypertension -A possible novel therapeutic target-

Session: Young Investigator Awards Session Basic Science

Topic: Chronic pulmonary hypertension

Speaker: Doctor T. Satoh (Pittsburgh, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Taijyu Satoh

University of Pittsburgh, Pittsburgh (United States of America)

0 follower

3 more presentations in this session

Loss of SRSF4 in cardiomyocytes induces hypertrophy, diastolic dysfunction and risk of sudden death

Speaker: Mr J. Larrasa-Alonso (Madrid, ES)

Molecular mechanisms of arrhythmia upon TBX5 loss

Speaker: Ms F. Rathjens (Göttingen, DE)

Innate immune nod1/rip2 signaling is essential for cardiac hypertrophic response with a surprising critical interaction with mitochondrial danger activator

Speaker: Doctor H. Lin (Ottawa, CA)

Access the full session

Young Investigator Awards Session Basic Science

Speakers: Doctor T. Satoh, Mr J. Larrasa-Alonso, Ms F. Rathjens, Doctor H. Lin

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources